S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

$9.07
-0.23 (-2.47%)
(As of 03/18/2024 ET)
Today's Range
$9.05
$9.37
50-Day Range
$7.78
$9.57
52-Week Range
$7.37
$11.56
Volume
563,135 shs
Average Volume
409,052 shs
Market Capitalization
$1.16 billion
P/E Ratio
113.45
Dividend Yield
N/A
Price Target
$9.40

Enfusion MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.80 Rating Score
Upside/​Downside
2.8% Upside
$9.33 Price Target
Short Interest
Healthy
3.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Enfusion in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$54,849 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.98 out of 5 stars

Computer And Technology Sector

534th out of 603 stocks

Prepackaged Software Industry

188th out of 206 stocks

ENFN stock logo

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

ENFN Stock News Headlines

They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Enfusion (NYSE:ENFN) Sees Strong Trading Volume
William Blair Reaffirms Their Buy Rating on Enfusion (ENFN)
The AI Bottleneck No One is Talking About
Renewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.
Earnings Outlook For Enfusion
Goldman Sachs Downgrades Enfusion (ENFN)
Enfusion to Host Investor Day on March 19, 2024
Enfusion downgraded to Underweight on client risks at JPMorgan
JP Morgan Downgrades Enfusion: Here's What You Need To Know
JPMorgan gets more bearish on Enfusion, downgrades shares
Enfusion: Product Is Sticky And Industry Is Huge
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/19/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+3.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
6 Analysts

Profitability

Net Income
$-7,650,000.00
Pretax Margin
6.58%

Debt

Sales & Book Value

Annual Sales
$174.54 million
Cash Flow
$0.14 per share
Book Value
$0.91 per share

Miscellaneous

Free Float
77,532,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.99
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 53)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 51)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Neal Pawar
    Chief Operating Officer
  • Ms. Valeria Gutowski (Age 42)
    Chief Accounting Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    General Counsel
  • Mr. Joseph Defeo
    Global Head of Managed Services Production
  • Mr. Jeff Young
    Head of Implementation

ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price target for 2024?

6 Wall Street research analysts have issued 1 year price targets for Enfusion's stock. Their ENFN share price targets range from $8.00 to $11.00. On average, they predict the company's share price to reach $9.33 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 at the start of the year. Since then, ENFN stock has decreased by 6.4% and is now trading at $9.0750.
View the best growth stocks for 2024 here
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ENFN earnings forecast
.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.

When did Enfusion IPO?

(ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by many different institutional and retail investors. Top institutional investors include Brown Capital Management LLC (9.27%), Vanguard Group Inc. (2.83%), Vanguard Group Inc. (2.83%), Wellington Management Group LLP (0.38%), Northern Trust Corp (0.27%) and Charles Schwab Investment Management Inc. (0.23%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners